Immunotherapy in mismatch repair-deficient colorectal cancers

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1120081

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

A new drug called PD-1 is effective in treating bowel cancers occurring in people at high risk of cancer called Lynch syndrome but little is known why PD-1 is effective at treating these cancer types. Initial studies have found that certain attributes of these cancers such as high amounts of inflammation may help to predict why these cancers respond to PD-1 but further studies of these tumors are needed to identify other tumor characteristics that may help predict responsiveness to PD-1.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2020

Funding Scheme: Early Career Fellowships

Funding Amount: $318,768.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Oncology and Carcinogenesis not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer epidemiology | cancer genetics | cancer immunology | cancer immunotherapy | cancer research

Related Links